These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37166279)

  • 21. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
    Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
    Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Wallbillich JJ; Morris RT; Ali-Fehmi R
    Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I
    Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma.
    Tamura N; Shaikh N; Muliaditan D; Soliman TN; McGuinness JR; Maniati E; Moralli D; Durin MA; Green CM; Balkwill FR; Wang J; Curtius K; McClelland SE
    Cancer Res; 2020 Nov; 80(22):4946-4959. PubMed ID: 32998996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
    Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X
    Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of CBX2 causes genomic instability and Wnt activation in high grade serous ovarian carcinoma cells.
    Ma Y; Liu L; Wei Z; Zhu M; Huang L; Wang S; Yi X; Ying F; Zhao S; Cai J; Wang Z; Sun S
    Mol Carcinog; 2023 Apr; 62(4):479-492. PubMed ID: 36621979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
    Chen H; Gotimer K; De Souza C; Tepper CG; Karnezis AN; Leiserowitz GS; Chien J; Smith LH
    Gynecol Oncol; 2020 Jun; 157(3):783-792. PubMed ID: 32253045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.
    Maenhoudt N; Defraye C; Boretto M; Jan Z; Heremans R; Boeckx B; Hermans F; Arijs I; Cox B; Van Nieuwenhuysen E; Vergote I; Van Rompuy AS; Lambrechts D; Timmerman D; Vankelecom H
    Stem Cell Reports; 2020 Apr; 14(4):717-729. PubMed ID: 32243841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting DNA repair: the genome as a potential biomarker.
    Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
    J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses.
    Vanderstichele A; Busschaert P; Smeets D; Landolfo C; Van Nieuwenhuysen E; Leunen K; Neven P; Amant F; Mahner S; Braicu EI; Zeilinger R; Coosemans A; Timmerman D; Lambrechts D; Vergote I
    Clin Cancer Res; 2017 May; 23(9):2223-2231. PubMed ID: 27852697
    [No Abstract]   [Full Text] [Related]  

  • 31. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.
    Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M
    Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A survey of cancer genome signatures identifies genes connected to distinct chromosomal instability phenotypes.
    Shafat MS; Rufaie ES; Watkins J
    Pharmacogenomics J; 2021 Jun; 21(3):390-401. PubMed ID: 33731882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models.
    Tadić V; Zhang W; Brozovic A
    Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189052. PubMed ID: 38097143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
    Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
    Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
    El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
    Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The genesis and evolution of high-grade serous ovarian cancer.
    Bowtell DD
    Nat Rev Cancer; 2010 Nov; 10(11):803-8. PubMed ID: 20944665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer.
    Paracchini L; Mannarino L; Romualdi C; Zadro R; Beltrame L; Fuso Nerini I; Zola P; Laudani ME; Pagano E; Giordano L; Fruscio R; Landoni F; Franceschi S; Dalessandro ML; Canzonieri V; Bocciolone L; Lorusso D; Bosetti C; Raspagliesi F; Garassino IMG; ; D'Incalci M; Marchini S
    Sci Transl Med; 2023 Dec; 15(725):eadi2556. PubMed ID: 38055801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
    Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
    Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.